Grass Pollen: A Double Threat to Allergy Patients
METHODOLOGY:
Researchers conducted an observational pilot study to assess the association between daily grass pollen concentrations and physical symptoms and daily life impairments experienced by patients with pollen allergy.
The analysis included 53 patients (mean age, 41.8 years; 68% women) with grass pollen-induced allergic rhinitis in Bavaria, Germany, evaluated between May and July 2022.
Researchers collected data for the pollen season 2022 from the Electronic Pollen Information Network of Bavaria. An app-based questionnaire was used to collect patients' data on allergic symptoms and treatment measures.
They used a physical symptoms index to assess patients' daily eye and nose symptoms and a daily overall impairments index to assess impairments in performance, sleep quality, and activities.
TAKEAWAY:
The average grass pollen concentration measured between early May and late July 2022 was 37.1 pollen particles/m 3 .
. A significant association was observed between grass pollen concentration and both the physical symptoms index (regression coefficient [beta], 0.002; P < .001) and impairments in day-to-day life (beta, 0.00064; P < .048).
< .001) and impairments in day-to-day life (beta, 0.00064; < .048). Additionally, pollen levels were significantly associated with performance impairment (beta, 0.0009; P = .027); no significant association was observed with sleep or daily activities.
IN PRACTICE:
'To enhance clinical practice, it is essential to address the gap in adequate medical care for pollen allergy patients and prioritize patient education on recognizing and managing allergic rhinitis,' the authors wrote. 'Advancements in technology-assisted self-monitoring could further empower patients in managing their symptoms and understanding the interplay between environmental triggers and allergic complaints,' they added.
SOURCE:
Jonas Huss, with the Bavarian Health and Food Safety Authority, Munich, Germany, was the corresponding author of the study, which was published online on May 28 in Scientific Reports.
LIMITATIONS:
The study relied on physician-diagnosed allergies and self-reported patient data. Additionally, the absence of individualized air pollution or weather data, a limited sample size, and strict exclusion criteria further limited the generalizability of the findings.
DISCLOSURES:
The study was funded by the Bavarian State Ministry of Health and Care. The authors reported having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
2 hours ago
- New York Times
As Earth Warms, California Fire Season Is Starting Earlier, Study Finds
California's main wildfire season is starting earlier in the year, and human-caused climate change is a major reason, new research finds. The onset of summertime fire activity in large parts of the state has crept into spring by up to two months since the early 1990s, according to a study published Wednesday in the journal Science Advances. The change has been especially pronounced in the Cascade Range in Northern California, the coastal mountains of Central California and coastal Southern California from Monterey to San Diego. Officials and disaster managers in the state now often speak of fire as a year-round hazard, instead of a seasonal threat. The study rules out two factors that might theoretically be behind the shift: buildups of vegetation and changes in the number of fires ignited, either accidentally or on purpose, by humans. The more important drivers, the researchers found, are the effects of greenhouse warming, including earlier and faster snowmelt and a warmer atmosphere that pulls more moisture out of soil and vegetation. Want all of The Times? Subscribe.
Newsweek
3 hours ago
- Newsweek
Donald Trump Threatens 250% Tariff on Pharmaceuticals
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has said that tariffs on pharmaceutical imports could eventually reach up to 250 percent, as his administration works to lower prescription prices for Americans. During an interview with CNBC on Tuesday, the president said he will initially impose a "small tariff on pharmaceuticals," which will rise to 150 percent "in one year, one and a half years maximum," before then eventually jumping to 250 percent. Newsweek reached out to the White House via email for comment. Why It Matters The United States imports a significant amount of pharmaceuticals each year—over $200 billion in 2024, according to the Observatory of Economic Complexity. Should Trump follow through on ramping up these duties, the highest he has threatened on the industry to date, experts believe this could result in significant increases to drug prices in the U.S. However, some health policy experts told Newsweek this could also help rebalance the global drug supply chain to better favor American customers. What To Know Trump said that the tariffs are intended to encourage pharmaceutical companies to move their operations to the U.S.—"because we want pharmaceuticals made in our country"—and to minimize reliance on Europe. He had previously threatened to place 200 percent tariffs on pharmaceuticals in July, but said he would give the industry time before this change came into effect. Trump's threats of pharmaceutical tariffs have raised concerns among experts that these could lead to increased costs and medication shortages in the U.S. In April, the UNC Center for the Business of Health published a report warning that these effects would be especially significant for generic drugs, which are more likely to be imported and operate on lower profit margins than brand-name medications. "A 250 percent tariff on pharmaceuticals would have a significant impact on drug prices," said health economist Jeromie Ballreich. Ballreich told Newsweek that, for branded pharmaceuticals, higher costs from the tariffs will be "passed on to consumers and most likely will be indirect through higher prescription drug insurance premiums." Major pharmaceutical companies across the world saw their shares fall on Wednesday following Trump's announcement. England-based AstraZeneca was down by 1.1 percent, Indiana-based Eli Lilly by 2.3 percent, and Germany-based Bayer AG by nearly 10 percent as of 11:20 ET. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, 2025. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, latest threat comes as the industry braces for the outcome of an ongoing probe by the Commerce Department into the national security implications of America's medicinal imports. The investigation was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Trump did not provide many specifics, such as whether certain classes of pharmaceuticals would be exempt, beyond stating that these tariffs are separate from the country-specific duties that came into effect last week. However, the announcement appears to contradict the terms of the European Union deal struck in July, which the European Commission president said placed a 15-percent tariff "ceiling" on multiple sectors, including pharmaceuticals. Experts had already warned that the 15 percent tariff outlined in the EU trade deal could end up costing the pharmaceutical industry billions. The cost implications could also be seen as conflicting with the administration's separate attempts to lower the price of prescription drugs. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, 2025. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, May, Trump signed an executive order directing the Secretary of Commerce and U.S. Trade Representative to "ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States." It also proposed that the U.S. be given Most-Favored-Nation (MFN) status, which would require drug companies to offer Americans the same lowest price that drugs are sold for in other countries. Trump followed this up by sending letters to 17 of the world's largest pharmaceutical companies on July 31, outlining steps they must take within 60 days to lower prescription prices for U.S. customers. These include extending MFN pricing to Medicaid, guaranteeing MFN pricing for new medications and negotiating "harder with foreign freeloading nations." The letters also call on the companies to expand direct-to-consumer distribution models to ensure customers "get the same low MFN prices that manufacturers already offer to third-party payers." "At face value, these tariffs are contradictory to his efforts to lower domestic prices," Ballreich told Newsweek. "However, if the tariffs are used as a threat to get drug companies to comply to his administration's [executive orders], including the recent letters to pharmaceutical CEOs, then I think we could see some changes to the pharmaceutical market, which will lower domestic drug prices." Several drugmakers, including Eli Lilly, AstraZeneca and Johnson & Johnson, have also pledged to expand their U.S. manufacturing presence. Prior to the letters being sent, but amid this pressure from the administration, a number had also announced they would be reducing some U.S. drug prices. Health policy analyst Mariana Socal warned that beyond potential cost implications, the tariffs could significantly disrupt the drug development pipeline, potentially jeopardizing the release of new medications. "Aside from the problem of added costs, the uncertainty introduced by tariff policies is detrimental in and of itself to the pharmaceutical market," she told Newsweek, noting that only around one in 10,000 investigated compounds make it to pharmacy shelves, and only do so after decades of work. "Any added uncertainty is likely to be detrimental to this industry, including disincentivizing investors from supporting this industry and pharmaceutical manufacturers from continuing to look for cures," she said. What People Are Saying Health economist Jeromie Ballreich told Newsweek: "This tariff could really disrupt the U.S. prescription drug market, especially the Medicare part D market, where the party plans will be on the hook for the higher price prices and result in significant premium increases to offset these higher prices. Given that, I don't think it's likely that this massive tariff will occur, but rather is a threat to force companies to find solutions based on the executive orders and his recent letters to pharmaceutical CEOs." Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, told Newsweek: "It is critical to continue to identify solutions to lower drug prices in America and improve drug affordability for Americans. However, it is unclear how tariffs would advance affordability. On the opposite, tariffs can be understood as a hidden tax." "In the short term, the likelihood that added costs from tariffs will be passed through to consumers can be reduced by existing contractual agreements with supply chain participants such as distributors and group purchasing organizations, which can protect buyers from price increases for 1-3 years," she added. "However, even if the added cost of tariffs would not necessarily be passed-through to patients in the short term, it could raise costs in the long run." What Happens Next On Sunday, Trump said he would be announcing tariffs on the industry "within the next week or so."
